25 43

Cited 0 times in

Efficacy and safety of onabotulinumtoxinA with standardized physiotherapy for the treatment of pediatric lower limb spasticity: A randomized, placebo-controlled, phase III clinical trial

Authors
 Rozalina Dimitrova  ;  Heakyung Kim  ;  Jill Meilahn  ;  Henry G Chambers  ;  Brad A Racette  ;  Marcin Bonikowski  ;  Eun Sook Park  ;  Emily McCusker  ;  Chengcheng Liu  ;  Mitchell F Brin 
Citation
 NEUROREHABILITATION, Vol.50(1) : 33-46, 2022-01 
Journal Title
NEUROREHABILITATION
ISSN
 1053-8135 
Issue Date
2022-01
MeSH
Botulinum Toxins, Type A* / therapeutic use ; Child ; Double-Blind Method ; Humans ; Lower Extremity ; Muscle Spasticity / drug therapy ; Neuromuscular Agents* / therapeutic use ; Physical Therapy Modalities ; Quality of Life ; Treatment Outcome
Keywords
Children ; lower limb ; onabotulinumtoxinA ; randomized clinical trial ; spasticity
Abstract
Background: Spasticity is common in cerebral palsy and can result in pain and diminished health-related quality of life.

Objective: To evaluate the safety and efficacy of onabotulinumtoxinA for lower limb spasticity treatment in children with cerebral palsy.

Methods: In this registrational phase 3, multinational, randomized, double-blind, placebo-controlled trial (NCT01603628), children (2-< 17 years) with cerebral palsy and ankle spasticity (Modified Ashworth Scale-Bohannon [MAS] score≥2) were randomized 1 : 1 : 1 to standardized physical therapy and onabotulinumtoxinA (4 or 8 U/kg), or placebo. Primary endpoint was average change from baseline at weeks 4 and 6 in MAS ankle score. Secondary endpoints included the Modified Tardieu Scale (MTS) and Global Attainment Scale (GAS).

Results: 381 participants were randomized. MAS scores averaged at weeks 4 and 6 were significantly reduced with both onabotulinumtoxinA doses (8 U/kg: -1.06, p = 0.010; 4 U/kg: -1.01, p = 0.033) versus placebo (-0.8). Significant improvements in average dynamic component of spasticity, measured by MTS, and in function, measured by GAS, were observed at several time points with both onabotulinumtoxinA doses versus placebo. Most adverse events were mild or moderate.

Conclusions: OnabotulinumtoxinA was well tolerated and effective in reducing lower limb spasticity and improving functional outcomes versus placebo in children.
Files in This Item:
T202202341.pdf Download
DOI
10.3233/NRE-210070
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Rehabilitation Medicine (재활의학교실) > 1. Journal Papers
Yonsei Authors
Park, Eun Sook(박은숙) ORCID logo https://orcid.org/0000-0002-9144-3063
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/189377
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links